We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
Read MoreHide Full Article
Ocugen (OCGN - Free Report) stock is up 378.7% this year so far against the industry’s decrease of 5.3%.
In February, Ocugen entered into a definitive agreement with India-based Bharat Biotech to co-develop and commercialize the latter’s COVID-19 vaccine, COVAXIN, for the U.S. market. This collaboration, which gave Ocugen U.S. rights to this lucrative vaccine candidate, has been driving the stock’s price this year so far. Ocugen is making progress toward Emergency Use Authorization (EUA) for COVAXIN in the United States. Ocugen is also in discussions with BARDA, regarding the U.S. government’s support of COVAXIN. It is also considering evaluating COVAXIN in special populations, such as children, as well as booster doses
In April, Bharat Biotech announced impressive data from the second interim analysis of its phase III study of COVAXIN, which showed 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection.
The company is also simultaneously driving its ophthalmology gene therapy pipeline toward clinical studies. It plans to submit an investigational new drug (“IND”) application for its gene therapy candidate, OCU400, in the second half of this year. The IND application seeks FDA’s approval to initiate two early-stage studies, anticipated to start by the end of 2021.
Some better-ranked stocks in the healthcare sector are BioNTech (BNTX - Free Report) , Atea Pharmaceuticals (AVIR - Free Report) and Repligen Corporation (RGEN - Free Report) . While BioNTech has a Zacks Rank of 1, the other two companies carry a Zacks Rank #2 (Buy).
BioNTech’s earnings estimates have risen from $10.91 per share to $29.44 per share for 2021 and from $7.34 per share to $21.34 per share for 2022 in the past 60 days. The stock is up 144.2% this year so far.
Atea’s earnings per share estimates have increased from $3.70 to $8.37 for 2021 and from $16.14 to $17.21 for 2022 over the past 60 days.
Repligen’s earnings estimates have risen from $1.91 to $2.21 for 2021 and from $2.23 to $2.53 for 2022 over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
Ocugen (OCGN - Free Report) stock is up 378.7% this year so far against the industry’s decrease of 5.3%.
In February, Ocugen entered into a definitive agreement with India-based Bharat Biotech to co-develop and commercialize the latter’s COVID-19 vaccine, COVAXIN, for the U.S. market. This collaboration, which gave Ocugen U.S. rights to this lucrative vaccine candidate, has been driving the stock’s price this year so far. Ocugen is making progress toward Emergency Use Authorization (EUA) for COVAXIN in the United States. Ocugen is also in discussions with BARDA, regarding the U.S. government’s support of COVAXIN. It is also considering evaluating COVAXIN in special populations, such as children, as well as booster doses
In April, Bharat Biotech announced impressive data from the second interim analysis of its phase III study of COVAXIN, which showed 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection.
The company is also simultaneously driving its ophthalmology gene therapy pipeline toward clinical studies. It plans to submit an investigational new drug (“IND”) application for its gene therapy candidate, OCU400, in the second half of this year. The IND application seeks FDA’s approval to initiate two early-stage studies, anticipated to start by the end of 2021.
Ocugen currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the healthcare sector are BioNTech (BNTX - Free Report) , Atea Pharmaceuticals (AVIR - Free Report) and Repligen Corporation (RGEN - Free Report) . While BioNTech has a Zacks Rank of 1, the other two companies carry a Zacks Rank #2 (Buy).
BioNTech’s earnings estimates have risen from $10.91 per share to $29.44 per share for 2021 and from $7.34 per share to $21.34 per share for 2022 in the past 60 days. The stock is up 144.2% this year so far.
Atea’s earnings per share estimates have increased from $3.70 to $8.37 for 2021 and from $16.14 to $17.21 for 2022 over the past 60 days.
Repligen’s earnings estimates have risen from $1.91 to $2.21 for 2021 and from $2.23 to $2.53 for 2022 over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>